By Sherri Oslick —

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

G.D. Searle
LLC et al. v. Lupin Pharmaceuticals, Inc. et al.
2:13-cv-00121;
filed March 5, 2013 in the Eastern District of Virginia

• Plaintiffs: 
G.D. Searle LLC; Pfizer Asia Pacific PTE, LTD.;
• Defendants: 
Lupin Pharmaceuticals, Inc.; Teva Pharmaceuticals USA, Inc.; Mylan
Pharmaceuticals Inc.; Watson Laboratories, Inc.; Apotex Inc.; Apotex Corp.

Infringement
of U.S. Patent No. RE44,048 ("4-[5-(4-Methylphenyl)-3-(Trifluoromethyl)-1H-Pyrazol-1-yl]Benzenesulfonamide
for the Treatment of Inflammation or an Inflammation-Associated Disorder,"
reissued march 5, 2013) in conjunction with defendants' filing of an ANDA to
manufacture a generic version of Pfizer's Celebrex® (celecoxib, used to treat osteoarthritis,
rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis,
acute pain, and primary dysmenorrhea). 
View the complaint here.

AbbVie Inc. et
al. v. The Kennedy Trust Rheumatology Research
1:13-cv-01358;
filed February 28, 2013 in the Southern District of New York

• Plaintiffs: 
AbbVie Inc.; AbbVie Biotechnology Limited
• Defendant: 
The Kennedy Trust Rheumatology Research

Declaratory
judgment of invalidity of U.S. Patent Nos. 8,298,537 ("Concomitant
Treatment of Rheumatoid Arthritis with Anti-TNF-α
Antibodies and Methotrexate," issued October 30, 2012) and 8,383,120 (same
title, issued February 26, 2013) in conjunction with Abbott's manufacture and
sale of its Humira® (adalimumab, used to treat rheumatoid arthritis, juvenile
idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's
disease and plaque psoriasis).  View the
complaint here.